Neonates are not just little children and need more finesse in dosing of antibiotics

References

• Hsieh EM, Hornik CP, Clark RH, et al. Medication use in the neonatal intensive care unit. Am J Perinatol. 2014;31:811–821.
   PubMed Web of Science ®Google Scholar
• Russell AB, Sharland M, Heath PT. Improving antibiotic prescribing in neonatal units: time to act. Arch Dis Child Fetal Neonatal Ed. 2012;97:F141–F146.10.1136/adc.2007.120709
   PubMed Web of Science ®Google Scholar
• Schulman J, Dimand RJ, Lee HC, et al. Neonatal intensive care unit antibiotic use. Pediatrics 2015;135:826–833.10.1542/peds.2014-3409
   PubMed Web of Science ®Google Scholar
• Kuzniewicz MW, Puopolo KM, Fisher A, et al. A quantitative, risk-based approach to the management of neonatal early-onset sepsis. JAMA Pediatr. 2017;171:365–371.10.1001/jamapediatrics.2016.4678
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Davidson L, Anguvaa L, et al. NICE neonatal early onset sepsis guidance: greater consistency, but more investigations, and greater length of stay. Arch Dis Child Fetal Neonatal Ed. 2015;100:F248–F249.10.1136/archdischild-2014-306349
   PubMed Web of Science ®Google Scholar
• Gilfillan M, Bhandari V. Biomarkers for the diagnosis of neonatal sepsis and necrotizing enterocolitis: Clinical practice guidelines. Early Hum Dev. 2017;105:25–33.10.1016/j.earlhumdev.2016.12.002
   PubMed Web of Science ®Google Scholar
• Stocker M, van Herk W, el Helou S, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicenter, randomised controlled trial (NeoPIns). Lancet 2017;390:871–881.10.1016/S0140-6736(17)31444-7
   PubMed Web of Science ®Google Scholar
• de Man P, Verhoeven BA, Verbrugh HA, et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000;355:973–978.10.1016/S0140-6736(00)90015-1
   PubMed Web of Science ®Google Scholar
• Allegaert K, van den Anker J. Neonatal drug therapy: The first frontier of therapeutics for children. Clin Pharmacol Ther. 2015;98:288–297.10.1002/cpt.v98.3
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E, Kaguelidou F, van den Anker JN. How to optimize the evaluation and use of antibiotics in neonates. Pediatr Clin North Am. 2012;59:1117–1128.10.1016/j.pcl.2012.07.004
   PubMed Web of Science ®Google Scholar
• Ward RM, Benjamin D, Barrett JS, et al. Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates. Pediatr Res. 2017;81:692–711.10.1038/pr.2016.221
   PubMed Web of Science ®Google Scholar
• Leroux S, Zhao W, Bétrémieux P, et al. Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey. Arch Dis Child. 2015;100:394–398.10.1136/archdischild-2014-306873
   PubMed Web of Science ®Google Scholar
• Spyridis N, Syridou G, Goossens H, et al. Variation in paediatric hospital antibiotic guidelines in Europe. Arch Dis Child. 2016;101:72–76.10.1136/archdischild-2015-308255
   PubMed Web of Science ®Google Scholar
• Metsvaht T, Nellis G, Varendi H, et al. High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination. BMC Pediatr. 2015;15:41.10.1186/s12887-015-0359-y
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/Pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother. 2011;55:4619–4630.10.1128/AAC.00182-11
   PubMed Web of Science ®Google Scholar
• Barker CI, Standing JF, Turner MA, et al. Antibiotic dosing in children in Europe: can we grade the evidence form pharmacokinetic/pharmacodynamic studies – and when is enough data enough? Curr Opin Infect Dis. 2012;25:235–242.10.1097/QCO.0b013e328353105c
   PubMed Web of Science ®Google Scholar
• Manolis E, Pons G. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br J Clin Pharmacol. 2009;68:493–501.10.1111/bcp.2009.68.issue-4
   PubMed Web of Science ®Google Scholar
• Fuchs A, Li G, van den Anker J, et al. Optimising β–lactam dosing in neonates: a review of pharmacokinetics, drug exposure and pathogens. Curr Pharm Des. 2017;23:5805–5838.
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E, Zhao W, Sharland M, et al. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med. 2013;18:28–34.10.1016/j.siny.2012.10.003
   PubMed Web of Science ®Google Scholar
• Allegaert K, Verbesselt R, Naulaers G, et al. Developmental pharmacology: neonates are not just small adults …. Acta Clin Belg. 2008;63:16–24.10.1179/acb.2008.003
   PubMed Web of Science ®Google Scholar
• Samardzic J, Allegaert K, Wilbaux M, et al. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period. Expert Opin Drug Metab Toxicol. 2016;12:367–375.10.1517/17425255.2016.1147559
   PubMed Web of Science ®Google Scholar
• Wilbaux M, Fuchs A, Samardzic J, et al. Pharmacometric approaches to personalize use of primarily renally eliminated antibiotics in preterm and term neonates. J Clin Pharmacol. 2016;56:909–935.10.1002/jcph.v56.8
   PubMed Web of Science ®Google Scholar
• Vieux R, Hascoet JM, Merdariu D, et al. Glomerular filtration rate reference values in very preterm infants. Pediatrics 2010;125:e1186–e1192.10.1542/peds.2009-1426
   PubMed Web of Science ®Google Scholar
• Allegaert K, Cossey V, Langhendries JP, et al. Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol Neonate. 2004;86:207–211.10.1159/000079618
   PubMedGoogle Scholar
• Zlotkin SH, Casselman CW. Percentile estimates of reference values for total protein and albumin in sera of premature infants (less than 37 weeks of gestation). Clin Chem. 1987;33:411–413.
   PubMed Web of Science ®Google Scholar
• Martin E, Fanconi S, Kälin P, et al. Ceftriaxone-bilirubin-albumin interactions in the neonate: An in vivo study. Eur J Pediatr. 1993;152:530–534.10.1007/BF01955067
   PubMed Web of Science ®Google Scholar
• Yanni SB, Smith PB, Benjamin DK Jr, et al. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm Drug Dispos. 2011;32:222–232.10.1002/bdd.v32.4
   PubMed Web of Science ®Google Scholar
• Oyaert M, Spriet I, Allegaert K, et al. Factors impacting unbound vancomycin concentrations in different patients populations. Antimicrob Agents Chemother. 2015;59:7073–7079.10.1128/AAC.01185-15
   PubMed Web of Science ®Google Scholar
• Smits A, Roberts JA, Vella-Brincat JW, et al. Cefazolin plasma protein binding in different human populations: More than cefazolin–albumin interaction. Int J Antimicrob Agents 2014;43:199–200.10.1016/j.ijantimicag.2013.10.008
   PubMed Web of Science ®Google Scholar
• Allegaert K, Mian P, van den Anker J. Developmental pharmacokinetics in neonates: maturational changes and beyond. Curr Pharm Des. 2017;23:5769–5778.
   PubMed Web of Science ®Google Scholar
• Muller AE, DeJongh J, Bult Y, et al. Pharmacokinetics of penicillin g in infants with a gestational age of less than 32 weeks. Antimicrob Agents Chemother. 2007;51:3720–3725.10.1128/AAC.00318-07
   PubMed Web of Science ®Google Scholar
• McCracken GH Jr, Ginsberg C, Chrane DF, et al. Clinical pharmacology of penicillin in newborn infants. J Pediatr. 1973;82:692–698.
   PubMed Web of Science ®Google Scholar
• Tremoulet A, Le J, Poindexter B, et al. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. Antimicrob Agents Chemother. 2014;58:3013–3020.10.1128/AAC.02374-13
   PubMed Web of Science ®Google Scholar
• Cies JJ, Fugarolas KN, Moore WS 2nd, et al. Population pharmacokinetics and pharmacodynamic target attainment of ampicillin in neonates with hypoxemic-ischemic encephalopathy in the setting of controlled hypothermia. Pharmacotherapy 2017;37:456–463.10.1002/phar.2017.37.issue-4
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Allegaert K. Clinical pharmacokinetics of amoxicillin in neonates. J Chemother. 2017;29:57–59.10.1179/1973947815Y.0000000064
   PubMed Web of Science ®Google Scholar
• De Cock RF, Smits A, Allegaert K, et al. Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. J Antimicrob Chemother. 2014;69:1330–1338.10.1093/jac/dkt527
   PubMed Web of Science ®Google Scholar
• Leroux S, Roué JM, Gouyon JB, et al. A population and developmental pharmacokinetic analysis to evaluate and optimize cefotaxime dosing regimen in neonates and young infants. Antimicrob Agents Chemother. 2016;60:6626–6634.10.1128/AAC.01045-16
   PubMed Web of Science ®Google Scholar
• van den Anker JN, Pokorna P, Kinzig-Schippers M, et al. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother. 2009;53:3871–3879.10.1128/AAC.00351-09
   PubMed Web of Science ®Google Scholar
• Shabaan AE, Nour I, Elsayed Eldegla H, et al. Conventional versus prolonged infusion of meropenem in neonates with Gram-negative late-onset sepsis: a randomized controlled trial. Pediatr Infect Dis J. 2017;36:358–363.10.1097/INF.0000000000001445
   PubMed Web of Science ®Google Scholar
• Cirillo I, Vaccaro N, Castaneda-Ruiz B, et al. Open-label study to evaluate the single-dose pharmacokinetics, safety, and tolerability of doripenem in infants less than 12 weeks in chronological age. Antimicrob Agents Chemother. 2015;59:4742–4749.10.1128/AAC.00485-15
   PubMed Web of Science ®Google Scholar
• van den Anker JN, Allegaert K. Pharmacokinetics of aminoglycosides in the newborn. Curr Pharm Des. 2012;18:3114–3118.10.2174/1381612811209023114
   PubMed Web of Science ®Google Scholar
• Rao SC, Srinivasjois R, Moon K. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev. 2016;12:CD005091.
   PubMedGoogle Scholar
• Low YS, Tan SL, Wan AS. Extended-interval gentamicin dosing in achieving therapeutic concentrations in Malaysian neonates. J Pediatr Pharmacol Ther. 2015;20:119–127.
   PubMedGoogle Scholar
• Fjalstad JW, Laukli E, van den Anker JN, et al. High-dose gentamicin in newborn infants: is it safe ? Eur J Pediatr. 2014;173:489–495.10.1007/s00431-013-2194-1
   Web of Science ®Google Scholar
• Sherwin CM, Broadbent RS, Medlicott NJ, et al. Individualising netilmicin dosing in neonates. Eur J Clin Pharmacol. 2008;64:1201–1208.10.1007/s00228-008-0536-0
   PubMed Web of Science ®Google Scholar
• Smits A, Kulo A, van den Anker J, et al. The amikacin research program: a stepwise approach to validate dosing regimens in neonates. Expert Opin Drug Metab Toxicol. 2017;13:157–166.10.1080/17425255.2017.1234606
   PubMed Web of Science ®Google Scholar
• Cristea S, Smits A, Kulo A, et al. Amikacin pharmacokinetics to optimize dosing in neonates with perinatal asphyxia treated with hypothermia. Antimicrob Agents Chemother. 2017;61(12):e01282–17.
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and Other antimicrobials in patients with staphylococcus AUREUS lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925–942.10.2165/00003088-200443130-00005
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E, Leroux S, Zhao W, et al. How to use vancomycin optimally in neonates: remaining questions. Expert Rev Clin Pharmacol. 2015;8:635–648.10.1586/17512433.2015.1060124
   PubMed Web of Science ®Google Scholar
• Padari H, Oselin K, Tasa T, et al. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target ? BMC Pediatr. 2016;8:206.10.1186/s12887-016-0753-0
   Google Scholar
• Leroux S, Jacqz-Aigrain E, Biran V, et al. Clinical utility and safety of a model-based patient-tailored dose of vancomycin in neonates. Antimicrob Agents Chemother. 2016;60:2039–2042.10.1128/AAC.02214-15
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. [ cited 2017 Nov 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Vancomycin_31/WC500238582.pdf
   Google Scholar
• Kaguelidou F, Turner MA, Choonara I, et al. Randomized controlled trials of antibiotics for neonatal infections: a systematic review. Br J Clin Pharmacol. 2013;76:21–29.10.1111/bcp.2013.76.issue-1
   PubMed Web of Science ®Google Scholar
• Standing JF, Anderson BJ, Holford NH, et al. Comment on pharmacokinetic studies in neonates: the utility of an opportunistic sampling design. Clin Pharmacokinet. 2015;54:1287–1288.10.1007/s40262-015-0344-5
   PubMed Web of Science ®Google Scholar
• Sherwin CM, Medlicott NJ, Reith DM, et al. Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child. 2014;99:590–594.10.1136/archdischild-2013-304887
   PubMed Web of Science ®Google Scholar